Su-Xia Luo
Overview
Explore the profile of Su-Xia Luo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
250
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen G, Sun D, Ba Y, Zhang Y, Zhou T, Zhao Y, et al.
J Hematol Oncol
. 2025 Feb;
18(1):15.
PMID: 39920751
Purpose: Open-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in patients with previously treated advanced nasopharyngeal carcinoma (NPC)...
2.
Ruan D, Liu F, Wei X, Luo S, Zhuang Z, Wang Z, et al.
Lancet Oncol
. 2025 Jan;
26(2):227-238.
PMID: 39788133
Background: CMG901 is a novel first-in-class antibody-drug conjugate with a humanised anticlaudin 18.2 antibody linked to microtubule-disrupting agent monomethyl auristatin E. We aimed to assess the antitumour activity and safety...
3.
Li N, Li Z, Fu Q, Zhang B, Zhang J, Wan X, et al.
Int J Surg
. 2024 Feb;
110(4):2071-2084.
PMID: 38320099
Background: The addition of immune checkpoint inhibitors to neoadjuvant chemotherapy in operable advanced gastric or gastroesophageal junction (G/GEJ) cancer aroused wide interest. This study was designed to assess the efficacy...
4.
Gu Y, Wang J, Lu W, Cheng Y, Tao R, Zhang S, et al.
Neurochem Res
. 2023 Aug;
48(12):3652-3664.
PMID: 37592110
Evidence demonstrates that DNA methylation is associated with the occurrence and development of various neurological diseases. However, the potential target genes undergoing DNA methylation, as well as their involvement in...
5.
Li N, Wu T, Hong Y, Guo Y, Cheng Y, Ma Y, et al.
BMC Med
. 2022 Dec;
20(1):472.
PMID: 36482345
Background: Anlotinib, a tyrosine kinase inhibitor, has shown encouraging anti-tumor activity in esophageal squamous cell carcinoma (ESCC). This study was designed to assess the efficacy and safety of anlotinib plus...
6.
Tang H, Yuan J, Gong Y, Zhang C, Liu M, Luo S
Front Genet
. 2022 Oct;
13:928256.
PMID: 36186483
Antibody-based cancer therapeutics is developing rapidly in recent years for its advantages in precisely targeting the tumor cells. However, tumor-specific cell surface antigens are still lacking, and the heterogeneity of...
7.
Bie L, Li N, Deng W, Lu X, Guo P, Luo S
BMC Mol Cell Biol
. 2021 Jun;
22(1):31.
PMID: 34074245
No abstract available.
8.
Niu L, Zhang Y, Huang T, Sun X, Luo S
Ann Transl Med
. 2021 Feb;
9(2):137.
PMID: 33569439
Background: Pathological examination of liver biopsies remains the gold standard for evaluating the stage of hepatic fibrosis, which are a number of disadvantages associated with biopsy. The aim of the...
9.
Wang G, Liu Y, Gao C, Wang Y, Lv H, Chen B, et al.
Ann Transl Med
. 2020 Sep;
8(15):947.
PMID: 32953747
Background: For the treatment of locally advanced (T4) gastric cancer, extended multi-organ resection remains controversial. This study aimed to evaluate the surgical outcomes and survival of patients with T4 gastric...
10.
Bie L, Li N, Deng W, Lu X, Guo P, Luo S
Onco Targets Ther
. 2020 Mar;
13:1705-1715.
PMID: 32158234
Purpose: miR-191 and miR-425 have been proved to be highly expressed in gastric carcinoma (GC). However, little research has been done on their clinical value in serum of patients with...